Shirin Hasan

Dr. Shirin Hasan

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
DMDimitrios Manolis
Dimitrios Manolis
SHShirin Hasan
Shirin Hasan
AMAnthony Maraveyas
Anthony Maraveyas
DODarragh P. O'BRien
Darragh P. O'BRien
BKBenedikt Kessler
Benedikt Kessler
LNLeonid Nikitenko
Leonid Nikitenko
The G protein-coupled receptor (GPCR) calcitonin receptor-like receptor (CLR) mediates essential functions in several cell types and is implicated in cardiovascular pathologies, skin diseases, migraine, and cancer. To date, the network of proteins interacting with CLR ("CLR interactome") in primary cells, where this GPCR is expressed at endogenous (physiologically relevant) levels, remains unknown. To address this knowledge gap, we established a novel integrative methodological workflow/approach for conducting a comprehensive/proteome-wide analysis of Homo sapiens CLR interactome. We used primary human dermal lymphatic endothelial cells and combined immunoprecipitation utilizing anti-human CLR antibody with label-free quantitative nano LC-MS/MS and quantitative in situ proximity ligation assay. By using this workflow, we identified 37 proteins interacting with endogenously expressed CLR amongst 4902 detected members of the cellular proteome (by quantitative nano LC-MS/MS) and revealed direct interactions of two kinases and two transporters with this GPCR (by in situ proximity ligation assay). All identified interactors have not been previously reported as members of CLR interactome. Our approach and findings uncover the hitherto unrecognized compositional complexity of the interactome of endogenously expressed CLR and contribute to fundamental understanding of the biology of this GPCR. Collectively, our study provides a first-of-its-kind integrative methodological approach and datasets as valuable resources and robust platform/springboard for advancing the discovery and comprehensive characterization of physiologically relevant CLR interactome at a proteome-wide level in a range of cell types and diseases in future studies.

6 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Saikat MandalSaikat Mandal
Saikat Mandal
MTMadeleine Taylor
Madeleine Taylor
AMAswin k Mohan
Aswin k Mohan
SHShirin Hasan
Shirin Hasan
MMManideepa Maji
Manideepa Maji
ADArkadeep Dhali
Arkadeep Dhali
Background: Parenteral iron is increasingly used to treat iron deficiency anaemia in patients with gastrointestinal cancer, particularly in the perioperative setting. However, concerns persist that intravenous iron could increase the risk of infection. We conducted a systematic review and meta-analysis to evaluate infectious complications and other relevant clinical outcomes after parenteral iron in gastrointestinal cancer. Methods: Embase, MEDLINE, CENTRAL and Scopus were searched from database inception to 20 February 2026, with additional records identified through citation searching. Comparative studies were eligible if they included adults with gastrointestinal cancer and compared parenteral iron with oral iron, placebo, no iron or standard care. Randomised and non-randomised comparative studies were included. The primary outcome was infection or infective complications. Secondary outcomes included length of hospital stay, hospital readmission and short-term mortality. Risk ratios (RRs) and mean differences (MDs) were pooled using random-effects models. Results: The search identified 2771 records. After removing 458 duplicates, 2313 records were screened, and 210 full texts were assessed. Fourteen comparative studies were included: four randomised controlled trials and ten non-randomised studies. Nine studies contributed to the primary infection analysis, including 899 patients receiving parenteral iron and 768 controls. Infection occurred in 126 patients in the parenteral iron group and 104 controls. Parenteral iron was not associated with an increased risk of infection (RR 1.07, 95% CI 0.71–1.62; p = 0.754; I2 = 57%). Restriction to randomised trials also showed no significant increase in infection risk (RR 1.17, 95% CI 0.56–2.43). Thirteen studies reported length of stay, with no meaningful difference between groups (MD: −0.05 days, 95% CI: −0.66 to 0.57). Four studies reported hospital readmission, with no significant difference between parenteral iron and control (RR 0.76, 95% CI 0.35–1.64; p = 0.480; I2 = 0%). Mortality analyses were event-limited, with no significant difference in 30-day mortality (RR 0.49, 95% CI 0.09–2.61) or 90-day mortality (RR 0.69, 95% CI 0.35–1.36). Conclusions: In patients with gastrointestinal cancer, parenteral iron was not associated with increased infection risk, prolonged hospital stay, higher readmission or increased short-term mortality. These findings provide reassuring evidence regarding the perioperative safety of parenteral iron, although confidence in the estimate is limited by observational evidence and heterogeneous definitions of infection.

25 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Saikat MandalSaikat Mandal
Saikat Mandal
SHShirin Hasan
Shirin Hasan
ADArkadeep Dhali
Arkadeep Dhali
MMManideepa Maji
Manideepa Maji
Background: Pancreatic ductal adenocarcinoma (PDAC) has a profoundly immunosuppressive tumour microenvironment (TME) that limits anti-tumour immunity and contributes to resistance to immunotherapy. Although γδ T-cells can integrate innate and adaptive immune signals, their abundance, transcriptional states and regulatory pathways in PDAC remain incompletely defined. Methods: We performed integrated single-cell RNA sequencing analysis of 39 pancreatic tissue samples, comprising 33 PDAC tumours and 6 adjacent normal tissues. After dataset integration, immune cell annotation, and stringent per-cell gating, γδ T-cells were quantified and profiled for checkpoint-, ligand-, and chemokine-related programmes. Results: γδ T-cells were detectable across PDAC samples but showed substantial inter-sample heterogeneity in abundance. Among candidate inhibitory pathways, PDCD1, CD274, and HAVCR2 expression in γδ T-cells did not differ significantly between tumour and adjacent tissues, whereas KLRC1 (encoding NKG2A) showed a tumour-associated difference at the single-cell level, with a consistent directional pattern in sample-level summaries. NKG2A expression was comparable between γδ T-cells and NK cells, suggesting a shared inhibitory programme. HLA-E, the ligand for NKG2A, showed higher epithelial-cell expression in tumour than adjacent tissue in sample-level summaries (median 1.06 vs. 0.57; BH-q = 0.035). Chemokine analysis identified enrichment of CCL2, CCL4, CCL5, CXCL8 and CXCL12, with limited CXCL9/10/11 signalling within the PDAC TME. Within γδ T-cells, CXCR4 was the trafficking receptor, followed by CCR6, CCR7 and CXCR6. Conclusions: PDAC-infiltrating γδ T-cells show marked inter-sample heterogeneity and variable inhibitory and trafficking-related programmes. Integrated transcriptomic analysis nominates HLA-E–NKG2A as a candidate regulatory axis, with NK cells included as a biologically relevant comparator. Chemokine receptor patterns, particularly CXCR4, CCR6, CCR7 and CXCR6, suggest candidate trafficking features. These findings are hypothesis-generating and require spatial, protein-level and functional validation.

19 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
DMDimitrios Manolis
Dimitrios Manolis
SHShirin Hasan
Shirin Hasan
CECamille Ettelaie
Camille Ettelaie
AMAnthony Maraveyas
Anthony Maraveyas
DODarragh P. O’Brien
Darragh P. O’Brien
LNLeonid Nikitenko
Leonid Nikitenko
Background: G protein-coupled receptor (GPCR) calcitonin receptor-like receptor (CLR) signalling is implicated in skin-related and cardiovascular diseases, migraine and cancer. However, beyond its agonists and receptor activity-modifying proteins (RAMPs), proteins which bind to CLR and define its properties in primary human cells remain insufficiently understood. Aim: We aimed to profile the CLR interactome in primary human dermal lymphatic endothelial cells (HDLEC), where this GPCR is expressed. Materials and methods: Immunoprecipitation (IP) of core- and terminally-glycosylated CLR from primary in vitro cultured HDLEC was conducted using rabbit polyclonal anti-human CLR serum (with pre- immune serum serving as a control) and confirmed by immunoblotting. Total HDLEC and co-immunoprecipitated CLR proteomes were analysed by label-free quantitative nano-liquid chromatography-tandem mass spectrometry (nLC-MS/MS). Quantitative in-situ proximity ligation assay (PLA) using ZEISS LSM 710 confocal microscope and ZEN Blue 3.0 and Image J software was performed to confirm nLC-MS/MS findings. All experiments were repeated at least three times (biological replicates). For statistical analysis of PLA data, distribution was analysed using Shapiro-Wilk normality test followed by an unpaired t -test or Mann-Whitney test with a p -value of ≤0.05 interpreted as significant. For MS data of CLR IP samples, statistical analysis was performed using t -test with a permutation-based false discovery rate (FDR)-adjusted p -value of ≤0.006 interpreted as significant. Results: A total of 4,902 proteins were identified and quantified by nLC-MS/MS in primary HDLEC and 46 were co-immunoprecipitated with CLR ( p< 0.006). Direct interaction with the GPCR was confirmed for five of these by PLA ( p <0.01). Conclusions: This is the first study of its kind to identify novel binding partners of CLR expressed in primary human cells. Our integrative quantitative approach, combining immunoprecipitation of core- and terminally-glycosylated CLR, nLC-MS/MS, and PLA, could be applied in a similar fashion to study its interactome in a variety of human cells and tissues, and its contribution to a range of diseases, where the role of this GPCR is implicated.

14 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SHShirin Hasan
Shirin Hasan
DMDimitrios Manolis
Dimitrios Manolis
ESEwan Stephenson
Ewan Stephenson
OROktawia A Ryskiewicz-Sokalska
Oktawia A Ryskiewicz-Sokalska
AMAnthony Maraveyas
Anthony Maraveyas
LNLeonid Nikitenko
Leonid Nikitenko
Background Calcitonin gene-related peptide (CGRP) is a 37-amino acid peptide that belongs to the calcitonin family of peptides together with adrenomedullin (AM), adrenomedullin 2 (AM2), also known as intermedin (IMD), amylin (AMY) and calcitonin. Recent reports demonstrated the efficacy of drugs targeting CGRP signalling axis for the treatment of migraine, but also revealed significant side effects such as inflammation and microvascular complications, including aberrant neovascularisation in the skin. These findings highlight the importance of studying cellular targets of CGRP in human tissues. Recent studies using animal models implicate the role of CGRP in lymphangiogenesis and lymphatic vessel function. However, whether CGRP has direct effects on lymphatic endothelial cells (LEC) remains unknown. Aim In this study, we analysed phosphorylation of p44/42 mitogen-activated protein kinases (MAPK) in proliferating primary human dermal LEC (HDLEC) stimulated with CGRP and compared with responses to AM2/IMD and AM. Materials and Methods Primary breast HDLEC from two female donors (39 and 46 years old) were cultured in vitro. Cell viability and proliferation of sub-confluent HDLEC were confirmed by MTS assay and Ki67 immunostaining. Phosphorylation of p44/42 MAPK in HDLEC treated with CGRP, AM2/IMD or AM at different time points (1-30 min) and concentrations (10-12-10-6M) was assessed by immunoblotting. All experiments have been performed at least 4 times. Statistical analysis was done using Shapiro-Wilk and Kruskal Wallis tests followed by uncorrected Dunn’s test, with p<0.05 interpreted as significant. Results CGRP induced p44/42 MAPK phosphorylation in a time- and dose-dependent manner in proliferating primary HDLEC from both donors. p44/42 MAPK phosphorylation was induced by all three peptides (10-6M) at 5-15 min (p<0.05), but only CGRP-stimulated effect was sustained at 30 min. CGRP consistently induced p44/42 MAPK phosphorylation at 10-7-10-6M (p<0.05) in HDLEC from both donors, whilst responses to AM2/IMD and AM varied. Conclusions Our study demonstrates that CGRP and AM2/IMD have direct effects on proliferating primary HDLEC. These new findings reveal CGRP and AM2/IMD as novel regulators of lymphatic endothelial cell biology and warrant further investigation of their roles in pathologies associated with lymphatic function in the skin and other organs.